Trial: 201905035

A Single-Arm Phase II Study with a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy with Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Phase

II

Principal Investigator

Vlacich, Gregory

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov